Fundraising FoxEnable Biosciences Inc.
Bay Area, US · 1 known investors
Find your way into Enable Biosciences Inc.
Sign up to see every warm intro you have to Enable Biosciences Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Enable Biosciences Inc. team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Enable Biosciences develops ultrasensitive antibody detection assays based on its Antibody Detection by Agglutination-PCR (ADAP) technology for diagnosing conditions including type 1 diabetes, celiac disease, food allergy, Lyme disease, and Zika/dengue. It offers testing services, custom assay development, and automated workstations for research and clinical diagnostics laboratories.
Founders & leadership
Investors · 1
Non-dilutive funding · 9 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $990K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.5M |
| National Science Foundation | Phase II | 2018 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $223.8K |
| National Science Foundation | Phase I | 2016 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $224.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Enable Biosciences Inc. do?
- Enable Biosciences develops ultrasensitive antibody detection assays based on its Antibody Detection by Agglutination-PCR (ADAP) technology for diagnosing conditions including type 1 diabetes, celiac disease, food allergy, Lyme disease, and Zika/dengue. It offers testing services, custom assay development, and automated workstations for research and clinical diagnostics laboratories.
- Who founded Enable Biosciences Inc.?
- Enable Biosciences Inc. was founded by Carolyn Bertozzi, Jason Tsai, Peter Robinson, David Seftel.
- Who are Enable Biosciences Inc.'s investors?
- Enable Biosciences Inc.'s investors include StartX.
- Where is Enable Biosciences Inc. headquartered?
- Enable Biosciences Inc. is headquartered in Bay Area, US.